UT-SAVIA-HEALTH
12.12.2022 13:53:42 CET | Business Wire | Press release
SaVia Health, a clinician-led healthcare SaaS company that creates and embeds patient care processes alongside electronic medical records (EMR), announced it raised an $8.5 million Seed round. The round was led by Intel Capital with participation from Kickstart, Peterson Ventures, Tom Burton, the founder of Health Catalyst, and Dr. Brent James, a professor at Stanford and renowned luminary in the healthcare quality improvement field.
SaVia Health was founded by a clinician, Dr. Will Caldwell, and a group of veteran healthcare software engineers led by David Edwards based in Salt Lake City, UT, seeking to provide clinicians with the ability to self-author clinical care pathways and provide clinical advice at the point of care.
“When I first saw clinicians using the SaVia tools, I knew the platform was something special. Never in my 21 years of clinical practice have I seen a piece of technology so fiercely embraced by clinicians,” said Dr. Will Caldwell, co-founder and CEO of SaVia Health. “Clinicians can finally design, implement, and modify care processes in a way that mirrors the rapidly evolving clinical landscape.”
“SaVia is a game changer when it comes to process redesign that enables deep operational and clinical improvement,” said Tom Burton, co-founder and Strategic Advisor of Health Catalyst. “With SaVia, dynamic workflow data capture changes can be made in minutes rather than weeks or months accelerating the speed of process improvement.”
Today, SaVia Health provides clinicians and administrators with a versatile software tool that transforms paper-based care processes into digital workflows, embedding them directly into the EMR. As a result, clinicians have real-time clinical advice at their fingertips. By standardizing care along best practice guidelines, mistakes are avoided and patients achieve better outcomes.
“Intermountain [Healthcare] caregivers have been using SaVia’s technology for years to provide the best possible care to our patients. SaVia’s tools enable front-line caregivers to consistently deliver best practices as part of their clinical workflows,” said Raj Srivastava, Senior Medical Executive Director at Intermountain Healthcare Delivery Institute. “We are thrilled to continue partnering with SaVia as an independent company to continue improving patient outcomes.”
“Patient care faces several challenges, including smoothly integrating the latest technology into existing processes,” said Nick Washburn, Senior Managing Director at Intel Capital. “SaVia is seamlessly changing the game for clinicians by translating data into guidance on what steps to take and when to best serve each patient.”
With this funding round, the company will further develop the self-authoring platform, expand its existing library of off-the-shelf applications, and focus on rapidly driving sales.
About SaVia Health
SaVia Health is a healthcare technology company based in Salt Lake City, UT that provides SaaS based process improvement software targeted at health systems, self-insured corporations, and large physician groups both in the United States and abroad. To learn more, visit saviahealth.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221212005152/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Investor Supporting Japan’s Entertainment Industry, Yoshihiro Shimamura, to Visit France Workshop to be Held During the Cannes Film Festival28.4.2026 04:00:00 CEST | Press release
Shimamura Yoshihiro Film Planning Inc. (Head Office: Osaka, Japan; CEO: Yoshihiro Shimamura), a company engaged in film production and investment, will host a workshop in France during this year’s Cannes Film Festival, as part of its commitment to further advancing the entertainment industry. The company invests in leading entertainment-related businesses in Japan and places strong emphasis on long-term value creation. It identifies the cultural and entertainment sectors as high-growth areas and is actively involved in international co-productions as a core part of its film production activities. As a recent investment, the company acquired 2,000,000 shares of Hankyu Hanshin Holdings, Inc.—a major Japanese entertainment conglomerate known for producing content enjoyed across generations—and became a major shareholder (as of March 25, 2026). Through such investments, the company aims to support the global expansion of Japanese entertainment while exploring synergies with its own interna
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
